Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC25B | P30305 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 4/20 | 0.51 |
| ▸ | RAB9A | P51151 | 3/20 | 0.51 |
| ▸ | NPC1 | O15118 | 2/20 | 0.51 |
| ▸ | HPGD | P15428 | 5/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 3/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | LTC4S | Q16873 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.46 |
| ▸ | GSTA1 | P08263 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | AR | P10275 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4675274 | 0.94 | CDC25B (0.55) | CDC25BMAPTRAB9ANPC1HPGD | |
| SCHEMBL28934347 | 0.90 | CDC25B (0.60) | CDC25BMAPTRAB9ANPC1HPGD | |
| SCHEMBL5153378 | 0.87 | CDC25B (0.48) | CDC25BMAPTRAB9ANPC1HPGD | |
| SCHEMBL6005099 | 0.84 | CDC25B (0.68) | CDC25BMAPTRAB9ANPC1HPGD | |
| SCHEMBL4840093 | 0.84 | AKR1C3 (0.58) | CDC25BMAPTRAB9ANPC1HPGD | |
| SCHEMBL30362007 | 0.82 | POLB (0.63) | MAPTHPGDKDM4EALDH1A1HTT | |
| SCHEMBL1221627 | 0.82 | POLB (0.63) | MAPTHPGDKDM4EALDH1A1HTT | |
| SCHEMBL5153184 | 0.82 | CDC25B (0.48) | CDC25BMAPTRAB9ANPC1HPGD | |
| Hydrochloric Acid SCHEMBL27134662 | 0.81 | POLB (0.61) | MAPTHPGDKDM4EALDH1A1POLB | |
| SCHEMBL27789892 | 0.80 | CTSD (0.60) | CDC25BRAB9ANPC1HTTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9012443-B2 | Bicyclic aryl and heteroaryl sodium channel inhibitors | AMGEN INC. (US) | 2015-04-21 | — | — | US | disclosed |
| US-9012443-B2 | Bicyclic aryl and heteroaryl sodium channel inhibitors | AMGEN INC. (US) | 2015-04-21 | — | — | US | disclosed |
| EP-2788332-A1 | BICYCLIC ARYL AND HETEROARYL SODIUM CHANNEL INHIBITORS | AMGEN, INC. (US) | 2014-10-15 | — | — | EP | disclosed |
| WO-2013086229-A1 | BICYCLIC ARYL AND HETEROARYL SODIUM CHANNEL INHIBITORS | AMGEN INC. (US) | 2013-06-13 | — | — | WO | disclosed |
| US-20130150339-A1 | Bicyclic Aryl and Heteroaryl Sodium Channel Inhibitors | AMGEN INC. (US) | 2013-06-13 | — | — | US | disclosed |
| WO-2013086229-A1 | BICYCLIC ARYL AND HETEROARYL SODIUM CHANNEL INHIBITORS | AMGEN INC. (US) | 2013-06-13 | — | — | WO | disclosed |
| US-20130150339-A1 | Bicyclic Aryl and Heteroaryl Sodium Channel Inhibitors | AMGEN INC. (US) | 2013-06-13 | — | — | US | disclosed |
| EP-1572672-B1 | BENZOXAZOCINES AND THEIR USE AS MONOAMINE-REUPTAKE INHIBITORS | SOSEI R & D LTD (GB) | 2008-08-13 | — | — | EP | disclosed |
| EP-1950206-A1 | Benzoxazocines and their use as monoamine-reuptake inhibitors | Sosei R&D Ltd. (GB) | 2008-07-30 | — | — | EP | disclosed |
| US-20060019940-A1 | Novel benzoxazocines and their therapeutic use | SOSEI R&D LTD. (GB) | 2006-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130150339-A1 | Bicyclic Aryl and Heteroaryl Sodium Channel Inhibitors | SCN1A, SCN1B, CACNA1B | CDC25B 3390/4885MAPT 3559/4885RAB9A 1283/4885 |
| US-20060019940-A1 | Novel benzoxazocines and their therapeutic use | HTR4, OPRM1, GRM4 | CDC25B 1814/4885MAPT 3319/4885RAB9A 2125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.